Frontotemporal dementia treatment: current symptomatic therapies and implications of recent genetic, biochemical, and neuroimaging studies.

Abstract

Frontotemporal dementia (FTD) is a common cause of dementia that encompasses 3 clinical subtypes: a behavioral/dysexecutive (frontal) variant and 2 variants with prominent language impairments. There are currently no Food and Drug Administration-approved medications for FTD although symptomatic treatments such as selective serotonin reuptake inhibitors and atypical antipsychotic agents are frequently used to manage behavioral abnormalities associated with this disorder. Evidence for the use of currently available symptomatic treatments in each FTD clinical subtype is reviewed. In addition, the implications of new genetic and neuropathologic information about FTD for the design of future clinical trials and the eventual development of FTD-specific disease-modifying treatments are discussed.

• Authors: Adam L Boxer, Bradley F Boeve
• Journal: Alzheimer disease and associated disorders (Alzheimer Dis Assoc Disord) 2007 Oct-Dec Vol. 21 Issue 4 Pg. S79-87 ISSN: 0893-0341 [Print] United States
• PMID: 18090429 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antipsychotic Agents
• Biomarkers
• Serotonin Uptake Inhibitors

Topics

• Antipsychotic Agents (therapeutic use)
• Behavioral Symptoms (drug therapy)
• Biomarkers
• Clinical Trials as Topic
• Dementia (drug therapy, genetics, physiopathology)
• Diagnostic Imaging
• Humans
• Selective Serotonin Reuptake Inhibitors (therapeutic use)